---
slug: 'novo-nordisk-dcf-valuation'
date: '11/29/2025'
title: 'Novo Nordisk DCF Valuation: Should you invest in the Ozempic and Wegovy Maker for exeptional returns?'
subtitle: 'Novo Nordisk went from breifly being Europe's largest company by market cap to declining 60% less than 6 months. A century-old pharmacheutical enterprise constantly innovating in blood-related illness , Novo Nordisk is investing heavily investing in scaling their existing businesses, at the same time, investing exceptionally well in finding cure for new illnesses. NVO's online prescription delivery business and international revenue segmant is showing impressive growth. Let's analyze Novo Nordisk fundamental and conduct an intrinsic valuation of the company.'
categories: 
['NVO', 'Novo Nordisk', 'Denmark', 'DCF Valuation', 'Signals', 'Valuation']
image: 'https://preview.redd.it/an-intrinsic-discounted-cash-flow-valuation-of-novo-nordisk-v0-3vb55nukya4g1.png?width=1587&format=png&auto=webp&s=32fe1bd929e5fbe311dcbf87674cce898cbc366e'
author: 'Kanchan'
---

# A Primer on Novo Nordisk

Ozempic Approvals: The initial FDA approval was granted for use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.Â  A new indication was approved to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established heart disease
